| アブストラクト | Objective: Magnesium oxide is widely used for treating opioid-induced constipation, a serious analgesic-associated problem. Opioid analgesic users are often prescribed non-steroidal anti-inflammatory drugs, which are sometimes combined with acid suppressants to prevent gastrointestinal adverse events. Magnesium preparations combined with acid suppressants may diminish magnesium preparations' laxative effect. This study was aimed at evaluating the effect of magnesium preparations combined with acid suppressants on the incidence of opioid-induced constipation by using the Food and Drug Administration Adverse Event Reporting System. Methods: Adverse events were defined per the Medical Dictionary for Regulatory Activities; the term 'constipation (preferred term code: 10010774)' was used for analysis. After adjusting for patient background factors using propensity score matching, acid suppressants' effect on constipation incidence was evaluated in opioid users prescribed magnesium preparations alone as laxatives by using a test for independence. Key Findings: The Food and Drug Administration Adverse Event Reporting System contains 14,475,614 reports for January 2004 to December 2021. Significantly increased constipation incidence was related to magnesium preparations combined with acid suppressants, especially proton pump inhibitors (P < 0.0001, McNemar's test). Conclusion: Magnesium preparations combined with acid suppressants may diminish magnesium preparations' laxative effect; healthcare professionals should pay attention to this issue. |
|---|
| ジャーナル名 | Die Pharmazie |
|---|
| 投稿日 | 2024/1/5 |
|---|
| 投稿者 | Maezawa, M; Inoue, M; Satake, R; Wakabayashi, W; Oura, K; Goto, F; Miyasaka, K; Hirofuji, S; Iwata, M; Suzuki, T; Tanaka, H; Nishida, S; Shimizu, S; Suzuki, A; Iguchi, K; Nakamura, M |
|---|
| 組織名 | Laboratory of Drug Informatics, Gifu Pharmaceutical Universit.;Laboratory of Drug Informatics, Gifu Pharmaceutical University.;Laboratory of Drug Informatics , Gifu Pharmaceutical University.;Laboratory of Drug Informatics, Gics, Gifu Pharmaceutical University.;Laboratory of Drug Informatics, Gifu Pharmaceutical University; Kifune Pharmacy.;Laboratory of Drug Informatics, Gifu Pharmaceutical University; Gifu Prefectural;Government.;Laboratory of Drug Informatics, Gifu Pharmaceutical University; Chubu Yakuhin Co.;Ltd.;Department of Pharmacy, Gifu University Hospital.;Laboratory of Community Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.;Laboratory of Drug Informatics, Gifu Pharmaceutical University; Corresponding;author: Mitsuhiro Nakamura, Laboratory of Drug Informatics, Gifu Pharmaceutical;University, 1-25-4 Daigaku-nishi, Gifu, 501-1196, Japan mnakamura@gifu-pu. ac.;jp. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38178284/ |
|---|
